Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib versus weekly paclitaxel in relapsed or progressive urothelial transitional cell carcinoma
2011-001841-34Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Pazopanib with Weekly paclitaxel (2 arms). Primary endpoint: Overall survival. Started Nov 2011; status: completed.
02
Drugs
pazopanibpaclitaxel
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2011-001841-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001841-34.